ASLAN Pharmaceuticals, Bristol-Myers Squibb partner to develop cancer treatment

SINGAPORE and PRINCETON, N.J. — Singapore-based ASLAN Pharmaceuticals and Bristol-Myers Squibb today announced a strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb''s investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors, according to a press release.

Under the terms of the agreement, ASLAN will receive exclusive rights to develop and commercialize BMS-777607 in China, Australia, Korea, Taiwan and other selected Asian countries while Bristol-Myers Squibb retains exclusive rights in the rest of the world.

"This ground-breaking partnership demonstrates how a leading Asian drug development company can work together with a global biopharmaceutical company to accelerate drug development and conduct early clinical studies in Asia in areas of significant unmet need," said Dr. Carl Firth, CEO of ASLAN.